University of North Carolina Hospitals Neuromuscular Medicine (Neurology)

Topics

• Myasthenia Gravis and Thymoma 154
• Peripheral Neuropathies and Disorders 46
• Amyotrophic Lateral Sclerosis Research 44
• Inflammatory Myopathies and Dermatomyositis 30
• Muscle Physiology and Disorders 20
• Amyloidosis: Diagnosis, Treatment, Outcomes 8
• Cancer Treatment and Pharmacology 8
• Peripheral Nerve Disorders 8
• Botulinum Toxin and Related Neurological Disorders 7
• Hereditary Neurological Disorders 7
• Neurogenetic and Muscular Disorders Research 6
• Pain Mechanisms and Treatments 6

Most cited

1. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.

   The Lancet. Neurology · 2021 · 608 citations · James Howard

2. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.

   The Lancet. Neurology · 2023 · 218 citations · James Howard

3. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.

   The Lancet. Neurology · 2023 · 236 citations · James Howard

4. Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis.

   Frontiers in neurology · 2023 · 78 citations · James Howard

5. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.

   NEJM evidence · 2022 · 186 citations · James Howard

6. A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.

   The New England journal of medicine · 2025 · 51 citations ·